These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7002822)

  • 1. Monoiodoinsulin specifically substituted in Tyr A14 or Tyr A19.
    Linde S; Hansen B
    Int J Pept Protein Res; 1980 May; 15(5):495-502. PubMed ID: 7002822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine A14[125I]monoiodoinsulin: Preparation, Biologic Properties, and long-term stability.
    Linde S; Hansen B; Sonne O; Holst JJ; Gliemann J
    Diabetes; 1981 Jan; 30(1):1-8. PubMed ID: 7014299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of monoiodoinsulin.
    Linde S; Hansen B
    Int J Pept Protein Res; 1974; 6(3):157-63. PubMed ID: 4415172
    [No Abstract]   [Full Text] [Related]  

  • 4. [125I]diiodoinsulins. Binding affinities, biologic potencies, and properties of their decay products.
    Pérez Maceda B; Linde S; Sonne O; Gliemann J
    Diabetes; 1982 Jul; 31(7):634-40. PubMed ID: 7160541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoiodoinsulin labelled in tyrosine residue 16 or 26 of the B-chain or 19 of the A-chain. II. Characterization of the kinetic binding constants and determination of the biological potency.
    Sonne O; Linde S; Larsen TR; Gliemann J
    Hoppe Seylers Z Physiol Chem; 1983 Feb; 364(2):101-10. PubMed ID: 6341199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoiodoinsulin labelled in tyrosine residue 16 or 26 of the insulin B-chain. Preparation and characterization of some binding properties.
    Linde S; Sonne O; Hansen B; Gliemann J
    Hoppe Seylers Z Physiol Chem; 1981 Jun; 362(6):573-9. PubMed ID: 7024083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for separate handling in vivo of different regions of the insulin molecule using A14- and B1-labeled insulin tracers.
    Cockram CS; Jones RH; Boroujerdi MA; Sönksen PH
    Diabetes; 1984 Aug; 33(8):721-7. PubMed ID: 6378697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A14-[125I]monoiodoinsulin purified by different high-performance liquid chromatographic procedures and by polyacrylamide gel electrophoresis: preparation, immunochemical properties and receptor binding affinity.
    Benzi L; Pezzino V; Marchetti P; Gullo D; Cecchetti P; Masoni A; Vigneri R; Navalesi R
    J Chromatogr; 1986 Jun; 378(2):337-47. PubMed ID: 3525587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heterogeneity of the immunoreactivity of A14, A19, B16 and B26- (125I) monoiodoinsulin to different species of anti-insulin immuno sera].
    Zhou W; Li S; Deng S
    Hua Xi Yi Ke Da Xue Xue Bao; 1993 Dec; 24(4):369-72. PubMed ID: 8150434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [127-I]- or carrier-free [125-I]monoiodoinsulin.
    Sodoyez JC; Sodoyez-Goffaux F; Goff MM; Zimmerman AE; Arquilla ER
    J Biol Chem; 1975 Jun; 250(11):4268-77. PubMed ID: 236316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Radioligand assay: methods and application. V. Mono-125I-insulin: preparation and immunological and biological characterization].
    Besch W; Woltanski KP; Knospe S; Ziegler M; Keilacker H
    Acta Biol Med Ger; 1980; 39(4):495-502. PubMed ID: 7004036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor binding and biological activity of specifically labeled [125I]- and [127I]monoiodoinsulin isomers in isolated rat adipocytes.
    Peavy DE; Abram JD; Frank BH; Duckworth WC
    Endocrinology; 1984 May; 114(5):1818-24. PubMed ID: 6370667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homogeneous mono-(125)i-insulins. Preparation and characterization of mono-(125)i-(tyr a14)-and mono-(125)i-(tyr a19)-insulin.
    Jørgensen KH; Larsen UD
    Diabetologia; 1980; 19(6):546-54. PubMed ID: 7007134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunochemical properties of A14-125I-monoiodoinsulin purified by high performance liquid chromatography.
    Benzi L; Marchetti P; Cecchetti P; Caricato F; Masoni A; Navalesi R
    J Nucl Med Allied Sci; 1984; 28(2):81-4. PubMed ID: 6392492
    [No Abstract]   [Full Text] [Related]  

  • 15. Monoiodoinsulin. Preparation, purification, and characterization of a biologically active derivative substituted predominantly on tyrosine A14.
    Hamlin JL; Arquilla ER
    J Biol Chem; 1974 Jan; 249(1):21-32. PubMed ID: 4809628
    [No Abstract]   [Full Text] [Related]  

  • 16. The synthesis of [A 19-3-iodotyrosine] and [A 19-3,5-diiodotyrosine]insulin (porcine).
    Wieneke HJ; Danho W; Büllesbach EE; Gattner HG; Zahn H
    Hoppe Seylers Z Physiol Chem; 1983 May; 364(5):537-50. PubMed ID: 6347860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological potency and binding affinity of monoiodoinsulin with iodine in tyrosine A14 or tyrosine A19.
    Gliemann J; Sonne O; Linde S; Hansen B
    Biochem Biophys Res Commun; 1979 Apr; 87(4):1183-90. PubMed ID: 465032
    [No Abstract]   [Full Text] [Related]  

  • 18. The degradation of monoiodotyrosyl insulin isomers by insulin protease.
    Ryan MP; Peavy DE; Frank BH; Duckworth WC
    Endocrinology; 1984 Aug; 115(2):591-9. PubMed ID: 6378594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoiodoinsulin specifically substituted on A19 tyrosine: preparation, c.
    Citti L; Battini L; Cecchetti P; Navalesi R
    J Nucl Med Allied Sci; 1977; 21(4):152-8. PubMed ID: 604426
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of radiochemical purity and tissue binding of labelled insulin prepared by lactoperoxidase and chloramine T iodination.
    Zórad S; Svábová E; Klimes I; Macho L
    Endocrinol Exp; 1985 Dec; 19(4):267-75. PubMed ID: 3910407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.